Conference Coverage

Most dermatologic drugs safe for breastfeeding mothers


 

EXPERT ANALYSIS FROM SUMMER AAD 2018

It’s best to avoid cosmetic topical products, but hydroquinone (L3), topical minoxidil (L2), and botulinum toxin A (L3) do not pose significant risk to the infant. Neither do the anesthetics lidocaine (L2) and epinephrine (L1) for breastfeeding women who need surgery.

Antibiotics

The vast majority of antibiotics are safe for women to use while breastfeeding, but a few notable exceptions exist, including erythromycin.

“People associate erythromycin as safe in lactation because it’s safe in pregnancy, but that’s not the case,” Dr. Murase pointed out. Erythromycin has been linked to pyloric stenosis in newborns and therefore should be avoided in the early months of breastfeeding. In older infants, however, erythromycin becomes an L1 medication.”

Tetracyclines fall into a borderline category. “Tetracyclines would be fine for a complicated infection,” but should not be used for more than 3 weeks, at which point they are regarded as L4, Dr. Murase said. “So long-term use of the tetracyclines should be avoided.”

Aside from these, topical antibiotics are considered safe. Women taking other oral antibiotics should be monitored for gastrointestinal symptoms or allergic responses.

Antifungals

As for antifungals, topicals are safe, and nystatin and clotrimazole are the best first-line options (both L1). Oral antifungals are similarly fine, with griseofulvin, fluconazole, ketoconazole, itraconazole, and terbinafine all classified as L2 and amphotericin B as L3.

If antifungals or antibiotics are being prescribed for a breast fungal infection or for mastitis, Dr. Murase underscored the importance of not stopping breastfeeding.

“The most important thing is that they continue to actually breastfeed on the affected breast that has the staph infection,” she said. She then reiterated that physicians should “reassure new mothers that the majority of oral and topical medications are safe.”

Dr. Murase disclosed serving on the advisory boards of Dermira, UCB, and Genzyme/Sanofi, and she has consulted for Ferndale and UpToDate.

Pages

Recommended Reading

Autoimmune connective tissue disease predicted by interferon status, family history
MDedge Dermatology
Bertilimumab granted orphan drug status for bullous pemphigoid
MDedge Dermatology
Orodental issues often associated with facial port-wine stains
MDedge Dermatology
Sprain an ankle, get an opioid
MDedge Dermatology
Skin signs may be good omens during cancer therapy
MDedge Dermatology
Pruritus linked to wide variety of cancers
MDedge Dermatology
IgA vasculitis may be more common in adults than assumed
MDedge Dermatology
FDA approves omadacycline for pneumonia and skin infections
MDedge Dermatology
Sunscreens: Misleading labels, poor performance, and hype about their risks
MDedge Dermatology
Beware drug reactions from methotrexate, voriconazole, and BRAF inhibitors
MDedge Dermatology